INR

PHM (TSX VENTURE:PHM) released July growth figures and disclosed it has achieved
a significant financial milestone less than one year after launching commercial
operations in September 2010. 


At the end of each month, PHM classifies revenue into two components:



1.  Existing Patient Services. PHM generates a recurring monthly revenue
    stream from enrolled weekly testers. 
2.  New Patient Enrollment. New patients add to the existing monthly revenue
    stream. 



Once enrolled, PHM ships a meter with an expected 5-year economic life to a
patient. With this meter investment, PHM generates monthly recurring revenue by
providing weekly monitoring services to the patient.


July 2011 Growth From New Patient Enrollment 

Understanding how many meters were shipped to newly enrolled patients each month
is relevant for analyzing growth because shipment of a meter is a prerequisite
to performing INR (1) tests eligible for reimbursement (2).


PHM shipped 138 meters in July 2011.

These new meters were shipped to patients who have been prescribed weekly INR
tests. If these new patients, along with the patients added in the fiscal third
quarter 2011, achieve compliance levels equal to those generated by existing
patients, the tests would generate additional annual revenues in excess of
$1,000,000 above and beyond the revenue reported for the quarter ending March
31, 2011. 


The growth over the past 4 months has resulted in PHM doubling its projected
annualized revenue (2).


Significant Financial Milestone 

As a result of PHM's recent growth, it has achieved operational break-even,
defined as Adjusted EBITDA before Patient Acquisition Costs (3). 


"This is a significant financial milestone for us," said Jaime Gerber, Chief
Strategic Officer and Interim Chief Executive Officer of PHM. "We now generate
more revenue than it costs to provide ongoing PST services including recurring
overhead. This contribution can be used to finance our growth rather than
relying solely on cash raised from our equity financing last June."


"With this important milestone behind us," continued Dr. Gerber, "we plan to
expand into more aggressive growth strategies to match the potential of the
market." 


(1) International normalized ratio ("INR") tests are used as measures of current
and future sales performance. Please refer to the "Non-GAAP Measures" section of
PHM's MD&A for further discussion on these operational measures.


(2) Management does not mean to suggest or imply that shipment of meters is
equivalent to revenue. Meter shipment is a prerequisite, but not a guaranty, of
revenue. Management does not propose meter shipments as a non-GAAP financial
measurement, because there is no simple reconciliation between meter shipment
and GAAP revenue.


(3) In calculating Adjusted EBITDA Before Patient Acquisition Costs certain
items are excluded from net loss including interest, taxes, amortization and
non-cash stock-based compensation and patient acquisition costs. Please refer to
the "Non-GAAP Measures" section of our MD&A for further discussion on these
operational measures.


About PHM 

PHM is a healthcare services company focused on providing in-home testing for
patients on blood thinner medications such as Coumadin(R) or warfarin. Medicare
recently expanded reimbursement for in-home patient self testing (PST) of blood
coagulation levels. PHM has a unique value proposition to cardiology groups that
manage patients on blood thinners, focusing on systemization to enroll patients
in PST. Current enrollment compliance levels may not be predictive of future
enrollment compliance levels. This unique, systemized approach creates an
opportunity for physician groups to operate more efficiently, increasing revenue
to their clinic while providing a higher standard of care for patients. 


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, changes in US healthcare laws, coverage or budgets,
dependence on few payors, possible new drug discoveries, a novel business model,
dependence on key suppliers, granting of permits and licenses in a highly
regulated business, competition, low profit market segments as well as general
economic, market and business conditions, and could differ materially from what
is currently expected.

(TSXV:INR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

(TSXV:INR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024